Passage BIO, Inc. - 10-Q Filing
Passage Bio, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2026, providing unaudited financial statements and updates on operations. The filing includes details about operating leases, equity incentive plans, research collaborations, and a subsequent event related to an arrangement with Gemma Biotherapeutics Inc.
Tickers: $PASG